

IPM Clinical Trials

IPM is a non-profit organization dedicated to developing microbicides and other innovative HIV prevention products, especially for women in developing countries. To that end, IPM and our research partners conduct clinical trials to evaluate the safety, acceptability and, ultimately, the efficacy of potential new products. Below is a list of research studies conducted to date or planned in the future.

DAPIVIRINE RING

TRIAL	DESCRIPTION	COUNTRIES	N*	STATUS
IPM 001	Dapivirine ring safety (Ring-001)	Belgium	12	Completed
IPM 008	Dapivirine ring safety (Ring-002)	Belgium	13	Completed
IPM 018	Dapivirine ring safety & PK (Ring 002 & 003)	Belgium	24	Completed
IPM 011	Placebo ring acceptability & safety	South Africa, Tanzania	170	Completed
IPM 024	Dapivirine ring safety & PK (Ring-004)	Belgium	16	Completed
IPM 013	Dapivirine ring safety & PK (Ring-004)	Belgium	48	Completed
IPM 015	Dapivirine ring safety (Ring-004)	Kenya, Malawi, South Africa, Tanzania	280	Data analysis
IPM 027 (The Ring Study)	Dapivirine ring safety & efficacy (Ring-004)	South Africa, other countries (TBD)	1650	Planned 2012
IPM 007A/B	Seroconverter protocol	Multiple countries in Africa	n/a	Planned 2012
MTN-020 (ASPIRE)	Dapivirine ring safety & efficacy (Ring-004)	Malawi, South Africa, Uganda, Zambia, Zimbabwe	3475	Planned 2012

NOTE: MTN-020 will be conducted by the NIH-funded Microbicide Trials Network. For more information, please visit: www.mtnstopshiv.org.

DAPIVIRINE-MARAVIROC COMBINATION RING

MTN-013 / IPM 026	Maraviroc ring, dapivirine ring, and dapivirine-maraviroc ring PK & safety	United States	48	Ongoing
----------------------	--	---------------	----	---------

DAPIVIRINE GEL

IPM 003	Dapivirine gel safety & PK (Gel-002)	Rwanda, South Africa, Tanzania	112	Completed
IPM 004	Dapivirine gel PK (Gel-002)	South Africa	18	Completed
IPM 005B	Dapivirine gel safety (Gel-002)	Belgium	36	Completed
IPM 012	Dapivirine gel PK & safety (Gels 4750 & 4789)	Belgium	36	Completed
IPM 020	Dapivirine gel safety (Gels 4759 & 4789)	United States	128	Data analysis
IPM 014A	Dapivirine gel safety & acceptability (Gel 4759)	Kenya, Malawi, Rwanda, South Africa	280	Data analysis
IPM 014B	Dapivirine gel safety & acceptability (Gel 4789)	South Africa	100	Data analysis
MTN-012 / IPM 010	Dapivirine gel male tolerance (Gel 4759)	United States	48	Data analysis

NOTE: The first Phase I safety trial of dapivirine gel (Gel-001) was conducted by Tibotec Pharmaceuticals among 52 women in Belgium.

* Estimated number of enrolled clinical trial participants (participants in all trials are women, except in MTN-012/IPM 010 which enrolled men).